The National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers and marketing companies to revise the Maximum Retail Price (MRP) of 17 life-saving drugs following exemption from Customs Duty under Ministry of Finance Notification 02/2026-Customs dated 01.02.2026. As MRP under DPCO, 2013 is inclusive of duties and taxes, the benefit of duty reduction must be passed on to consumers through appropriate price revision and Form V submission.
The National Pharmaceutical Pricing Authority (NPPA) has instructed manufacturers and marketing companies to revise the Maximum Retail Price (MRP) of 17 life-saving drugs exempted from Customs Duty under Ministry of Finance Notification No. 02/2026-Customs dated 01 February 2026.
Key points include:
- As per the provisions of the Drugs (Prices Control) Order (DPCO), 2013, the MRP of drugs and formulations is inclusive of applicable taxes and duties. Therefore, any reduction in duties must be reflected in the retail price, ensuring that the financial benefit is passed on to consumers.
- Companies are required to submit revised price information through Form V and issue updated price lists or supplementary price lists to dealers, State Drug Controllers, and the Government.
The directive reinforces price transparency and consumer protection in the pharmaceutical sector.